Elin Roos1, Daniela Mariosa2, Caroline Ingre1, Cecilia Lundholm1, Karin Wirdefeldt1, Per M Roos1, Fang Fang1. 1. From the Departments of Medical Epidemiology and Biostatistics (E.R., D.M., C.L., K.W., F.F.) and Clinical Neuroscience (C.I., K.W.), and Institute of Environmental Medicine (P.M.R.), Karolinska Institutet, Stockholm, Sweden; and Department of Neurology (P.M.R.), Division of Clinical Neurophysiology, Oslo University Hospital, Oslo, Norway. 2. From the Departments of Medical Epidemiology and Biostatistics (E.R., D.M., C.L., K.W., F.F.) and Clinical Neuroscience (C.I., K.W.), and Institute of Environmental Medicine (P.M.R.), Karolinska Institutet, Stockholm, Sweden; and Department of Neurology (P.M.R.), Division of Clinical Neurophysiology, Oslo University Hospital, Oslo, Norway. Daniela.Mariosa@ki.se.
Abstract
OBJECTIVE: To examine the relative risk of depression among patients with amyotrophic lateral sclerosis (ALS), both in terms of depression diagnosis and use of antidepressant drugs, before and after diagnosis. METHODS: We conducted a nested case-control study including 1,752 patients with ALS diagnosed from July 2005 to December 2010 and 8,760 controls based on the Swedish national health and population registers, to assess the associations of depression diagnosis and use of antidepressant drugs with a subsequent risk of ALS. We further followed the patients with ALS after diagnosis to estimate the association of an ALS diagnosis with the subsequent risk of depression and use of antidepressant drugs. RESULTS: Before diagnosis, patients with ALS were at higher risk of receiving a clinical diagnosis of depression compared to controls (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.3-2.3), and the highest risk increase was noted during the year before diagnosis (OR 3.5, 95% CI 2.1-5.6). Patients with ALS also had a highly increased risk of depression within the first year after diagnosis (hazard ratio 7.9, 95% CI 4.4-14.3). Antidepressant use was more common in patients with ALS than in controls, especially during the year before (OR 5.8, 95% CI 4.5-7.5) and the year after (hazard ratio 16.1, 95% CI 11.5-22.6) diagnosis. CONCLUSIONS: Patients with ALS are at higher risk of depression diagnosis and use of antidepressant drugs both immediately before and after diagnosis.
OBJECTIVE: To examine the relative risk of depression among patients with amyotrophic lateral sclerosis (ALS), both in terms of depression diagnosis and use of antidepressant drugs, before and after diagnosis. METHODS: We conducted a nested case-control study including 1,752 patients with ALS diagnosed from July 2005 to December 2010 and 8,760 controls based on the Swedish national health and population registers, to assess the associations of depression diagnosis and use of antidepressant drugs with a subsequent risk of ALS. We further followed the patients with ALS after diagnosis to estimate the association of an ALS diagnosis with the subsequent risk of depression and use of antidepressant drugs. RESULTS: Before diagnosis, patients with ALS were at higher risk of receiving a clinical diagnosis of depression compared to controls (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.3-2.3), and the highest risk increase was noted during the year before diagnosis (OR 3.5, 95% CI 2.1-5.6). Patients with ALS also had a highly increased risk of depression within the first year after diagnosis (hazard ratio 7.9, 95% CI 4.4-14.3). Antidepressant use was more common in patients with ALS than in controls, especially during the year before (OR 5.8, 95% CI 4.5-7.5) and the year after (hazard ratio 16.1, 95% CI 11.5-22.6) diagnosis. CONCLUSIONS:Patients with ALS are at higher risk of depression diagnosis and use of antidepressant drugs both immediately before and after diagnosis.
Authors: J G Rabkin; S M Albert; M L Del Bene; I O'Sullivan; T Tider; L P Rowland; H Mitsumoto Journal: Neurology Date: 2005-07-12 Impact factor: 9.910
Authors: Nis P Suppli; Christoffer Johansen; Jane Christensen; Lars V Kessing; Niels Kroman; Susanne O Dalton Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Mengyang Feng; Nicole A Crowley; Akshilkumar Patel; Yao Guo; Sierra E Bugni; Bernhard Luscher Journal: Neuroscience Date: 2019-03-08 Impact factor: 3.590
Authors: Magdalena Kuzma-Kozakiewicz; Peter M Andersen; Katarzyna Ciecwierska; Cynthia Vázquez; Olga Helczyk; Markus Loose; Ingo Uttner; Albert C Ludolph; Dorothée Lulé Journal: Neurology Date: 2019-08-07 Impact factor: 9.910
Authors: Tara Peseschkian; Isabell Cordts; René Günther; Benjamin Stolte; Daniel Zeller; Carsten Schröter; Ute Weyen; Martin Regensburger; Joachim Wolf; Ilka Schneider; Andreas Hermann; Moritz Metelmann; Zacharias Kohl; Ralf A Linker; Jan Christoph Koch; Boriana Büchner; Ulrike Weiland; Erik Schönfelder; Felix Heinrich; Alma Osmanovic; Thomas Klopstock; Johannes Dorst; Albert C Ludolph; Matthias Boentert; Tim Hagenacker; Marcus Deschauer; Paul Lingor; Susanne Petri; Olivia Schreiber-Katz Journal: Brain Sci Date: 2021-03-14
Authors: Benedetta Izzi; Alfonsina Tirozzi; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Marc F Hoylaerts; Licia Iacoviello; Alessandro Gialluisi Journal: Int J Mol Sci Date: 2020-11-21 Impact factor: 5.923